Board Member
Nautilus Biotechnology, Inc. (NAUT)Equibles does not estimate personal net worth.
Get an email with a short summary when Nautilus Biotechnology, Inc. publishes a filing, an earnings call transcript or a press release.
Get NAUT alertsSujal Patel is recorded as Board Member at Nautilus Biotechnology, Inc. (NAUT) since January 1, 2021 and CEO at Nautilus Biotechnology, Inc. (NAUT). The newest filing on record that lists Sujal Patel as CEO and Board Member at Nautilus Biotechnology, Inc. (NAUT) is dated April 28, 2026. The proxy statement of Nautilus Biotechnology, Inc. reports total compensation of $1,418,556 for Sujal Patel in fiscal 2025, including a base salary of $535,000. Disclosed compensation is on record for 6 fiscal years. Sujal Patel has spoken on 22 earnings calls across 1 company, most recently for Nautilus Biotechnology, Inc. on October 27, 2026. Nautilus Biotechnology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Nautilus Biotechnology, Inc. includes Anna Mowry (CFO), Matt Murphy (General Counsel), Matthew Murphy (General Counsel) and 7 others.
“Last quarter, I walked you through a deliberate decision to concentrate our resources on proteiform. This quarter, I want to talk to you about what proteoforms are and why we believe they're one of the most important opportunities in life sciences, and how we're building the foundation for meaningful long-term growth.”
“We've spent the last nine years building what I believe is one of the most innovative platforms in life sciences. It produces a layer of biological insight that we believe does not exist anywhere else in the world today.”
“Before turning to the quarter, I'd like to begin by recapping the Q1 announcements we highlighted on our last earnings call.”
“Before turning to the quarter, I want to briefly remind everyone of what we're building and why we believe it matters.”
“Q3 was another important quarter for Nautilus. We made meaningful progress across our scientific platform and operational priorities as we continue our disciplined path toward commercialization.”
2021-01-01–present
Last confirmed April 28, 2026
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
CEO, Board Member
2021-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $535,000 | $1,418,556 |
| 2024 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $535,000 | $1,961,393 |
| 2023 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $535,000 | $1,892,862 |
| 2022 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $500,000 | $1,757,772 |
| 2021 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $436,731 | $6,605,335 |
| 2020 | Nautilus Biotechnology, Inc. (NAUT) | President, Chief Executive Officer and Secretary | $200,000 | $251,450 |
